dm+d

321995004

Articles

Choosing a suitable antidepressant for people with coronary heart disease (CHD)

2 July 2021Prescribers may need to choose a safe antidepressant in people with CHD. We guide on available options. We do not cover management of complex depression.

Safety in Lactation: Antidepressants

21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Monamine-oxidase inhibitors (MAOIs) Due to the…

How do you switch between tricyclic, SSRI and related antidepressants?

21 October 2019This updated Medicines Q&A provides advice on the risks and suggested strategies for switching between tricyclic (TCA), selective serotonin reuptake inhibitors (SSRI) and related antidepressants.…

If antidepressant-induced hyponatraemia has been diagnosed, how should the depression be treated?

10 June 2019This Medicines Q&A evaluates the evidence available on the management of depression in patients with antidepressant-induced hyponatraemia. Summary Most antidepressants are associated with hyponatraemia, with…
Search Articles

Medicine Compliance Aid Stability

EdronaxPfizer Ltd

Pfizer Ltd
Edronax
Tablets 4mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
17 January 2022

Lactation Safety Information

TCA: imipramine/nortriptyline SSRI: paroxetine/sertraline
Very limited published evidence of safety indicates small amounts in breast milk
Monitor infant for drowsiness, poor feeding, irritability/behavioural effects
5 June 2018

New Medicines

Narcolepsy and associated cataplexy (sudden loss of muscle tone triggered by strong emotions)

Information

New formulation (repurposed medicine)
Axsome Therapeutics
Axsome Therapeutics

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Category

Selective norepinephrine reuptake inhibitor
Prevalence is estimated as 25 per 100,000 in Caucasian populations, more frequent in males [2]
Narcolepsy and associated cataplexy (sudden loss of muscle tone triggered by strong emotions)
Oral